Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT01999361
NA

Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

Sponsor: Rodolfo Alejandro

View on ClinicalTrials.gov

Summary

This is a single-center, prospective, open label study in islet transplant recipients after complete islet graft rejection/loss, defined as stimulated c-peptide ≤0.3 ng/mL.

Official title: Myfortic® Monotherapy to Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

18

Start Date

2009-01

Completion Date

2028-12

Last Updated

2026-03-23

Healthy Volunteers

No

Interventions

DRUG

Myfortic

treatment with myfortic

Locations (1)

Diabetes Research Institute

Miami, Florida, United States